"The implications are huge, absolutely huge, " says Harvard Medical School's Christopher Cannon, who led the Lipitor-versus-Pravachol study.

FORBES: Pills for Everyone!

Christopher Cannon, a cardiologist at Boston's Brigham and Women's Hospital, became involved with Merck's cardiovascular safety trials of Vioxx and Arcoxia in January 2002.

FORBES: The Vioxx Safety Study Merck Didn't Do

Over the long haul, says Dr. Christopher Cannon of the Brigham and Women's Hospital in Boston, the goal should be to prevent future episodes through more aggressive lowering of cholesterol and treatment with more anticlotting agents.

CNN: Just How Bad Was It?

"We were delighted to find that patients who get the current state-of-the-art treatment with platelet blockers, medical treatment and stents during procedures had a significant improvement in their outcome, " said Dr. Christopher Cannon, an assistant professor at Harvard Medical School and a principal investigator for a number of heart-related studies at Brigham and Women's Hospital in Boston, Massachusetts.

CNN: Research closing in on heart disease